Huma Qamar, MD, MPH, CMI
@drhumaqamar
Followers
2K
Following
534
Media
94
Statuses
400
Physician|Chief Medical Officer at Ocugen , Inc|Public Health | Clinical Strategist
United States
Joined March 2014
It was my absolute pleasure and honor to meet with Congressman Pete Sessions!! @PeteSessions !!
3
14
84
World Blindness Awareness Month!!
This #WorldBlindnessAwarenessMonth we recognize patients facing vision loss and are committed to transforming care through our modifier #genetherapy platform addressing major blindness diseases. Learn more about clinical trials currently enrolling: https://t.co/seNeE2TdZq
1
5
45
We’re advancing clinical research in Stargardt disease! Ocugen is now enrolling U.S. patients for our Phase 2/3 OCU410ST-101/301 trial, starting at age 3. Learn more: NCT05956626 | clinical.request@ocugen.com #ClinicalTrials #StargardtDisease #GeneTherapy
0
20
94
Thanks @ModernRetina for the feature!!
Our Luminance Dependent Navigation Assessment tool, used in the OCU400 Phase 3 liMeliGhT trial, was featured in @ModernRetina as a more sensitive measurement to assess visual function in RP. Thanks to Ocugen authors @drhumaqamar & Dr. Chavali. Read more: https://t.co/eo7jzrOMRR
0
7
65
At the @HCWCO 27th Annual Global Investment Conf, Ocugen CEO and CMO shared updates on our strategy and progress in advancing gene therapies to address blindness diseases with high unmet need. Watch the recap: https://t.co/7SXsya1ro2
#GeneTherapy #HealthcareInnovation
0
20
93
Advances in Pediatric Retina 2025.
Our CMO, Dr. Huma Qamar, will present at the Advances in Pediatric Retina Course on Sept 19, 2025, highlighting progress in pediatric retinal disease diagnosis & management. More info: https://t.co/BhgwgIkV81
#APR2025 #PediatricRetina #Ophthalmology #HealthcareInnovation
1
6
42
TUFH 2025 Ocugen Poster Presentations OCU400, OCU410ST and OCU410 GA.
1
10
70
EXCITING NEWS: Ocugen signs agreement with Kwangdong for exclusive Korean rights for first regional gene therapy partnership. 25% royalties & potentially $180M+ in sales milestones in 10 yrs. 🌍 Read more: https://t.co/WXtPcVETbh
#GeneTherapy #GlobalPartnerships
0
41
205
HCWO Global Investment Conference
Ocugen CEO Dr. Shankar Musunuri and CMO Dr. Huma Qamar will speak at the @HCWCO Global Investment Conf (Sept. 8–10, NYC). Dr. Musunuri will also speak at Biotech on Tap 2025 (Sept. 24–26, Munich). Learn more: https://t.co/elz3bCkqXp
#Biotech #GeneTherapy #Investment
2
4
52
EAP OCU400
Hear from Evan, a retinitis pigmentosa (RP) patient who participated in the OCU400 Expanded Access Program (EAP). To learn more about the OCU400 EAP or Phase 3 liMeliGhT clinical trial, email clinical.request@ocugen.com or call 484-237-3390. #RetinitisPigmentosa
1
20
79
Hear from Evan, a retinitis pigmentosa (RP) patient who participated in the OCU400 Expanded Access Program (EAP). To learn more about the OCU400 EAP or Phase 3 liMeliGhT clinical trial, email clinical.request@ocugen.com or call 484-237-3390. #RetinitisPigmentosa
0
21
94
Recently, @MollyBOfficial spoke with Dr. Lejla Vajzovic about how Ocugen’s Phase 3 LiMeliGhT clinical trial is providing hope to all RP patients—regardless of mutation or stage of the disease. Learn more: clinical.request@ocugen.com | 484-237-3390 #RetinitisPigmentosa
0
13
75
Retina World Congress (RWC) 2025 updates!!
❗From #RetinaWorldCongress❗ Dr. Huma Qamar highlighted @Ocugen's gene therapy platforms for retinitis pigmentosa, #Stargardtdisease and GA, including plans for upcoming biologics license applications. https://t.co/ZVMh4WHBkJ
#Vision #Retina @RWCRetina @drhumaqamar
1
15
63
Poster presentations OCU410ST and OCU410GA at Women in Ophthalmology (WIO) conference
3
10
64
Earnings August, 2025!!!
We're making bold strides in gene therapy for blindness. ✅ Promising OCU410 data ✅ Phase 3 OCU400 on track ✅ Dosing initiated for Phase 2/3 confirmatory trial for Stargardt ✅ Strategic partnership + OrthoCellix launch Read more: https://t.co/IUrRAUjeOc
#GeneTherapy #Biotech
1
10
58
WIO 2025!!
🧬Ocugen will attend #WIO2025 in Amelia Island, FL! Dr. Majda Hadziahmetovic will present on OCU410 for geographic atrophy. @drhumaqamar will present on OCU410ST for Stargardt disease. Both on Aug 9 at 11 AM EST. Details: https://t.co/TmS29FO9o9
#GeneTherapy #Ophthalmology
1
8
51
We are honored to attend ASRS – American Society of Retina Specialists 2025—a premier meeting for retina science and innovation—taking place July 30–August 2 at the Long Beach Convention and Entertainment Center.
Excited to attend #ASRS2025 in Long Beach! 🧬 Dr. Syed Shah on Gene Therapy for RP – Aug 1 🧬 Dr. Jay Chhablani on OCU410 – Aug 2 🧬 Dr. Ramiro Moldanado’s e-poster on OCU410ST More info 👉 https://t.co/miUbk8HZWG
#GeneTherapy #RetinaResearch #Biotech
0
12
65
Inspired by voices like @MollyBOfficial’s, we’re advancing science to potentially provide a gene therapy to all RP patients. Ocugen’s Phase 3 OCU400 liMeliGhT trial is currently enrolling. 📩 clinical.request@ocugen.com 📞 484-237-3390 #OCU400 #RP #GeneTherapy #ClinicalTrials
0
34
141
Big news! We’ve dosed the first patient in our Phase 2/3 GARDian3 trial for #Stargardtdisease (OCU410ST). With no approved treatment today, this huge milestone brings us one step closer to helping patients with this blindness disease. Details: https://t.co/R7hId9bAvo
0
31
143
📅SAVE THE DATE: Ocugen's 2Q 2025 business update is on Friday, Aug 1, 2025, at 8:30 A.M. ET. Tune in for key clinical and regulatory updates + financial results. 🔗 https://t.co/vP6FwMvDjm
#Ocugen #BiotechNews #GeneTherapy #InvestorUpdate #SaveTheDate
0
26
105